

draft guidance builds on the voluntary Phase I (2.5-year) sodium reduction goals issued in October 2021. When finalized, the draft guidance will describe our views on the next voluntary goals (Phase II (3-year)) for sodium reduction in a variety of identified categories of foods that are commercially processed, packaged, or prepared. The 3-year goals are intended to balance the need for broad and gradual reductions in sodium and what is publicly known about technical and market constraints on sodium reduction and reformulation. The distribution of sodium concentrations in currently available products in each category was a significant factor in developing these quantitative sodium concentration goals. We developed the goals with a particular emphasis on maintaining concentrations needed for food safety, given the function of salt as a food preservative. The Phase II goals are within the range of concentrations found in currently marketed foods and are feasible using existing technical strategies.

We note that we do not intend to finalize the draft long-term (10-year) sodium reduction goals that were included in the 2016 draft of the first edition of the guidance that we announced in the **Federal Register** of June 2, 2016 (81 FR 35363). We plan to announce any future sodium reduction goals via draft guidance.

## II. Paperwork Reduction Act of 1995

While the guidance contains no collection of information, it does refer to previously approved FDA collections of information. The previously approved collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3521). The collections of information in 21 CFR part 101 have been approved under OMB control number 0910–0381. The collections of information in 21 CFR 101.11 have been approved under OMB control number 0910–0782.

## III. Electronic Access

Persons with access to the internet may obtain the draft guidance at <https://www.fda.gov/FoodGuidances>, <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>, or <https://www.regulations.gov>. Use the FDA website listed in the previous sentence to find the most current version of the guidance.

## IV. References

The following references are on display at the Dockets Management Staff

(see **ADDRESSES**) and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; they are also available electronically at <https://www.regulations.gov>. Although FDA verified the website addresses in this document, please note that websites are subject to change over time.

1. Harnack L.J., M.E. Cogswell, J.M. Shikany, et al. "Sources of Sodium in U.S. Adults From 3 Geographic Regions." *Circulation*, 135 (May 9, 2017): pp. 1775–1783. Available at: <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.024446> (accessed December 26, 2023).
2. U.S. Department of Agriculture and U.S. Department of Health and Human Services. "Dietary Guidelines for Americans, 2020–2025." 9th Edition. December 2020. Available at: <https://www.dietaryguidelines.gov/> (accessed December 26, 2023).
3. National Academies of Sciences, Engineering, and Medicine. "Dietary Reference Intakes for Sodium and Potassium" (March 2019). Washington, DC: The National Academies Press. Available at: <http://www.nationalacademies.org/hmd/Reports/2019/dietary-reference-intakes-sodium-potassium.aspx> (accessed December 26, 2023).

Dated: August 9, 2024.

**Lauren K. Roth,**

*Associate Commissioner for Policy.*

[FR Doc. 2024–18261 Filed 8–15–24; 8:45 am]

**BILLING CODE 4164–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Meeting of the National Advisory Committee on Rural Health and Human Services

**AGENCY:** Health Resources and Services Administration (HRSA), Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** In accordance with the Federal Advisory Committee Act, this notice announces that the Secretary's National Advisory Committee on Rural Health and Human Services (NACRHHS) has scheduled its semiannual meeting. Information about NACRHHS and the agenda for this meeting can be found on the NACRHHS website at <https://www.hrsa.gov/advisory-committees/rural-health/index.html>.

**DATES:** Wednesday, September 4, 2024, 9 a.m.–5 p.m. mountain daylight time (MDT); Thursday, September 5, 2024, 9

a.m.–5 p.m. MDT; Friday, September 6, 2024, 9 a.m.–12 p.m. MDT.

**ADDRESSES:** The meeting will be conducted in two separate locations. On September 4, 2024, the meeting will commence at the Hilton Santa Fe Historic Plaza Hotel, 100 Sandoval Street, Santa Fe, New Mexico, 87501. That afternoon, the meeting will resume at the Historic Plaza Hotel, 230 Plaza Street, Las Vegas, New Mexico 87701. Telephone: (505) 425–3591. The Plaza Hotel will be the physical location for both the September 5 and September 6 meetings.

The meeting will also be accessible to the public virtually via Zoom. The meeting details are included below. There is no need to register for this meeting. If joining virtually, please use the following information. This is the link for all days of the meeting:

Join Zoom Meeting <https://us02web.zoom.us/j/81769614451>.

Meeting ID: 817 6961 4451.

One tap mobile

+13052241968,,81769614451# US  
+19294362866,,81769614451# US (New York)

Dial by your location

- +1 305 224 1968 US
- +1 929 436 2866 US (New York)
- +1 301 715 8592 US (Washington, DC)
- +1 312 626 6799 US (Chicago)
- +1 669 900 6833 US (San Jose)
- +1 253 215 8782 US (Tacoma)
- +1 346 248 7799 US (Houston)

Meeting ID: 817 6961 4451.

Find your local number: <https://us02web.zoom.us/j/81769614451>.

#### FOR FURTHER INFORMATION CONTACT:

Sahira Rafiullah, Designated Federal Officer of NACRHHS, 5600 Fishers Lane, Rockville, Maryland 20857; 240–316–5874; or [srafiullah@hrsa.gov](mailto:srafiullah@hrsa.gov).

#### SUPPLEMENTARY INFORMATION:

NACRHHS provides advice and recommendations to the Secretary of Health and Human Services on policy, program development, and other matters of significance concerning both rural health and rural human services. At this meeting the committee will discuss the opioid crisis and its impact on rural families. The emphasis will be on prevention efforts but will include related discussions of treatment and recovery. At this meeting, NACRHHS will discuss the availability of disability services in rural areas. Members of the public will have the opportunity to provide comments. Public participants wishing to provide oral comments must submit a written version of their comments at least 3 business days in advance of the scheduled meeting. Oral comments will be honored in the order they are requested and may be limited

as time permits. Public participants wishing to offer written comments should send them to Sahira Rafiullah, using the contact information above, at least 3 business days prior to the meeting. Individuals who plan to attend either physically or virtually and need special assistance or other reasonable accommodation should notify Sahira Rafiullah through any of the methods listed above, at least 10 business days prior to the meeting.

**Maria G. Button,**

*Director, Executive Secretariat.*

[FR Doc. 2024–18370 Filed 8–15–24; 8:45 am]

**BILLING CODE 4165–15–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Eunice Kennedy Shriver National Institute of Child Health and Human Development Special Emphasis Panel; Medical Rehabilitation Research Resource (P50 Clinical Trial Optional).

*Date:* November 4–5, 2024.

*Time:* 10:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Child Health and Human Development, 6710B Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Helen Huang, Ph.D., Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6710B Rockledge Drive, Room 2137D, Bethesda, MD 20892, (301) 496–8558, [helen.huang@nih.gov](mailto:helen.huang@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: August 13, 2024.

**Lauren A. Fleck,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024–18409 Filed 8–15–24; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Interventional Agents Safety and Pharmacokinetic Services (IASPS).

*Date:* September 10–13, 2024.

*Time:* 12:00 p.m. to 7:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3E70A, Rockville, MD 20892 (Video Assisted Meeting).

*Contact Person:* Soheyla Saadi, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3E70A, Rockville, MD 20892, (240) 669–5178, [saadisoh@niaid.nih.gov](mailto:saadisoh@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: August 13, 2024.

**Lauren A. Fleck,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024–18410 Filed 8–15–24; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Center for Advancing Translational Sciences (NCATS), both institutes of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Autala Bio Inc., A Civala Company (“Autala”), incorporated in Delaware.

**DATES:** Only written comments and/or applications for a license that are received by the National Heart Lung and Blood Institute (NHLBI) Office of Technology Transfer And Development (OTTAD) on or before September 3, 2024 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Jillian Varonin, Ph.D., Technology Transfer Manager, NHLBI Office of Technology Transfer And Development, Telephone: (301) 496–0505; Email: [jillian.varonin@nih.gov](mailto:jillian.varonin@nih.gov).

#### SUPPLEMENTARY INFORMATION:

##### Intellectual Property

1. United States Provisional Patent Application No. 61/624,741, filed April 16, 2012, entitled “Derivatives Of Docosahexaenoylamide and Uses Thereof” [HHS Reference No. E–070–2012–0–US–01];

2. PCT Patent Application No. PCT/US2013/032333, filed March 15, 2013, entitled “Derivatives Of Docosahexaenoylamide and Uses Thereof” [HHS Reference No. E–070–2012–0–PCT–02];

3. European Patent No. 2847178, filed March 15, 2013, entitled “Derivatives Of Docosahexaenoylamide and Uses Thereof” [HHS Reference No. E–070–2012–0–EP–03];

4. United States Patent No. 9,422,308, filed September 23, 2014, entitled “Derivatives Of Docosahexaenoylamide